References
- Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003;25:169–78
- Lindena G, Arnau H, Liefhold J. Hydromorphon – pharmakologische eigenschaften und therapeutische wirksamkeit. Schmerz 1998;12:195–204
- Sohn VW. Hydromorphon – ein starkes opioid mit vorteilen bei der verstoffwechselung. Fortschr Med 2003;121:51–5
- Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497–504
- Lötsch J. Opioid metabolites. J Pain Symptom Manage 2005;29:S10–S24
- Parab PV, Coyle DE, Streng WH, et al. Biopharmaceutic parameters of hydromorphone and in-vitro evaluation of its tablet and suppository dosage form. Pharm Ind 1987;49:951–65
- Verma RJ, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Controlled Release 2002;79:7–27
- Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97:827–36
- Summary of product characteristics for JURNISTA. Mountain view (CA): ALZA corporation
- Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 2007;7:3 [doi:10.1186/1472-6904-7-3]
- Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007;7:2 [doi:10.1186/1472-6904-7-2]
- US Food and Drug Administration. FDA alert [07/2005]. Alcohol–palladone interaction. Available from: http://www.fda.gov/cder/drug/infopage/palladone/default.htm
- OPANA® ER (oxymorphone hydrochloride) extended-release tablets prescribing information. Endo Pharmaceuticals Inc 2007. Available from: http://www.opana.com/pdfs/opana_er_pi.pdf
- International center for alcohol policies. International drinking guidelines. ICAP reports 14 December 2003
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657–80
- Wallace MS, Thipphawong J. Clinical trial results with OROS® hydromorphone. J Pain Symptom Manage 2007;33:S25–S32